Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $11.00 at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its target price boosted by HC Wainwright from $8.00 to $11.00 in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms also recently issued reports on SANA. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.25.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $4.30 on Wednesday. The firm has a market cap of $960.06 million, a price-to-earnings ratio of -3.07 and a beta of 1.45. The firm has a fifty day moving average price of $2.39 and a 200 day moving average price of $4.07. Sana Biotechnology has a fifty-two week low of $1.52 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, research analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its position in Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after acquiring an additional 4,438,949 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after purchasing an additional 276,055 shares during the period. State Street Corp grew its holdings in Sana Biotechnology by 4.2% during the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after purchasing an additional 269,274 shares during the last quarter. Integral Health Asset Management LLC raised its position in Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after purchasing an additional 220,000 shares during the period. Finally, Barclays PLC lifted its stake in Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after purchasing an additional 178,179 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.